Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs

OBJECTIVES: Tofacitinib is an oral Janus kinase inhibitor for treatment of psoriatic arthritis (PsA). We evaluated patient-reported outcomes (PROs) in patients with PsA refractory to ≥1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR) and tumour necrosis factor inhibitor-naïv...

Descripción completa

Detalles Bibliográficos
Autores principales: Strand, Vibeke, de Vlam, Kurt, Covarrubias-Cobos, Jose A, Mease, Philip J, Gladman, Dafna D, Graham, Daniela, Wang, Cunshan, Cappelleri, Joseph C, Hendrikx, Thijs, Hsu, Ming-Ann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340575/
https://www.ncbi.nlm.nih.gov/pubmed/30713721
http://dx.doi.org/10.1136/rmdopen-2018-000806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340575/
https://www.ncbi.nlm.nih.gov/pubmed/30713721
http://dx.doi.org/10.1136/rmdopen-2018-000806

Ejemplares similares